Nelson BE, O'Brien S, Sheth RA, et al. Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer 2025;13:e010013. doi: 10.1136/jitc-2024-010013
In this article figures 1 and 2 have been updated:
Figure 1.
Figure 2.
For accuracy
Corrected the cohort labeling both at the bottom of the figure and in the graph legend to ensure consistency with the manuscript.
For clarity and Readability
Moved the cohort legend to the bottom of the graph for better visualization.
Relabeled the graph legend of Inj. Lesion Recist Response/ Overall Recist response to Injected Lesion RECIST/ Overall RECIST
The color coding of dose level 6 was changed from bright yellow to cyan for improved readability.
Standardized abbreviations, such as colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and castration-resistant prostate cancer (CRPC).
Introduced additional symbols: (*) to indicate crossover patients and (¶) to denote an unconfirmed partial response (PR) to enhance interpretability.
For accuracy
In figure 2A(CD4+analysis), the percentage was corrected from 63% to 64% to reflect the accurate calculation.
In figure 2C, the color coding was corrected in the graph legend for the 2000 µg dose level, changing it from green to orange for consistency with the figure.